Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 2,266,096 | 1,857,601 | 1,681,432 | 1,363,302 | 1,297,662 |
| Cost of Goods | 1,426,029 | 1,156,683 | 1,037,473 | 832,210 | 825,002 |
| Gross Profit | 840,067 | 700,918 | 643,959 | 531,092 | 472,660 |
| Operating Expenses | 508,713 | 413,319 | 406,880 | 324,853 | 294,992 |
| Operating Income | 331,383 | 288,282 | 237,552 | 206,449 | 177,670 |
| Interest Expense | 63,772 | 29,777 | 27,709 | 15,072 | 11,950 |
| Other Income | 14,070 | 38,450 | 13,078 | 4,051 | 11,875 |
| Pre-tax Income | 281,681 | 296,955 | 222,921 | 195,428 | 177,595 |
| Income Tax | 54,463 | 171,369 | 66,835 | 43,391 | 47,671 |
| Net Income Continuous | 227,218 | 125,586 | 156,086 | 152,037 | 129,924 |
| Net Income Discontinuous | 1,506 | -137 | 280 | -950 | -1,726 |
| Minority Interests | 2,351 | 2,094 | 1,601 | 1,774 | 1,500 |
| Net Income | $226,373 | $123,355 | $154,765 | $149,313 | $126,698 |
| EPS Basic Total Ops | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 |
| EPS Basic Continuous Ops | 4.69 | 2.60 | 3.28 | 3.23 | 2.76 |
| EPS Basic Discontinuous Ops | 0.03 | 0.00 | 0.01 | -0.02 | -0.04 |
| EPS Diluted Total Ops | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 |
| EPS Diluted Continuous Ops | 4.59 | 2.54 | 3.22 | 3.15 | 2.70 |
| EPS Diluted Discontinuous Ops | 0.03 | 0.00 | 0.01 | -0.02 | -0.04 |
| EPS Diluted Before Non-Recurring Items | 6.03 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $493,162 | $419,441 | $364,210 | $301,330 | $275,840 |